MRI  Vol.3 No.1 , February 2014
Reduction of pro-inflammatory cytokines in rats following 7-day oral supplementation with a proprietary eggshell membrane-derived product
ABSTRACT
NEM® brand eggshell membrane is a novel dietary supplement that has been clinically shown to alleviate arthritis joint pain and stiffness; however the mechanism of action is not well understood. Preliminary evidence from an in vitro study of NEM® indicated that the mechanism of action may be based on the reduction of pro-inflammatory cytokines. In vivo studies were therefore initiated to evaluate the effects of NEM® on pro-inflammatory and anti-inflammatory cytokines following oral administration in rats. NEM® was administered daily at doses of 6.13 mg/kg bw/day (Study 1), 10.0 mg/kg bw/day (Study 2), or at doses of 0 (control), 26.0 or 52.0 mg/kg bw/day (Study 3) by oral gavage for 7 consecutive days. Inflammation was induced in the Study 3 rats by intraperitoneal injection of lipopolysaccharide. Changes in plasma cytokine levels from baseline following 7 days of oral supplementation with NEM® at 6.13 mg/kg bw/ day (Study 1) were statistically significant at Day 8 for IL-2, TIMP-1 and VEGF, at Day 21 for IL-10, and at Day 35 for MCP-1, MCP-3 and TIMP-1, and at 10.0 mg/kg bw/day (Study 2) were statistically significant at Day 8 for VEGF, at Day 21 for MIP-1β, MIP-2 and VEGF, and at Day 35 for MCP-3, MIP-1β, MIP-2 and VEGF. Changes in serum cytokine levels versus control at 26.0 mg/kg bw/day (Study 3) were statistically significant at all time-points for IL-1β and at 1.5 hours for IL-10, and at 52.0 mg/kg bw/day (Study 3) were statistically significant at 1.5 hours for IFN-γ, IL-1β and IL-10, and at 3 hours for IL-1β, and at 24 hours for IL-10. Taken together, these studies demonstrate that oral supplementation with NEM® can influence both early-phase pro-inflammatory cytokines like IL-1β and TNF-α (Study 3), as well as later-phase cytokines like MCP-1, MIP-1α & β, RANTES and VEGF (Study 1 & 2). These studies provide a possible basis for the mechanism of action of NEM® in vivo.

Cite this paper
Ruff, K. and DeVore, D. (2014) Reduction of pro-inflammatory cytokines in rats following 7-day oral supplementation with a proprietary eggshell membrane-derived product. Modern Research in Inflammation, 3, 19-25. doi: 10.4236/mri.2014.31003.
References
[1]   Harringman, J.J., Ludikhuize, J. and Tak, P.P. (2004) Chemokines in joint disease: The key to inflammation? Annals of the Rheumatic Diseases, 63, 1186-1194. http://dx.doi.org/10.1136/ard. 2004.020529

[2]   Martel-Pelletier, J., Alaaeddine, N. and Pelletier, J.P. (1999) Cytokines and their role in the pathophysiology of osteoarthritis. Frontiers in Bioscience, 4, d694-d703. http://dx.doi.org/10.2741/ Martel

[3]   Choy, E.H.S. and Panayi, G.S. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine, 344, 907-916. http://dx.doi.org/10.1056/NEJM20010 3223441207

[4]   Feldmann, M. and Maini, R.N. (2008) Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunological Reviews, 223, 7-19. http://dx.doi.org/10.1111/j. 1600-065X.2008.00626.x

[5]   Brennan, F.M. and McInnes, I.B. (2008) Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigations, 118, 3537-3545. http://dx.doi.org/10.1172/JCI36389

[6]   Kokkonen, H., Soderstrom, I., Rocklov, J., Hallmans, G., Lejon, K. and Dahlqvist, S.R. (2010) Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis & Rheumatism, 62, 383-391. http://dx.doi.org/10.1002/art.27186

[7]   Dixon, W.G., Suissa, S. and Hudson, M. (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: Systematic review and meta-analyses. Arthritis Research & Therapy, 13, R139. http://dx.doi.org/10.1186/ar3453

[8]   Singh, G., Wu, O., Langhorne, P. and Madhok, R. (2006) Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-analysis. Arthritis Research & Therapy, 8, 153-162. http://dx.doi.org/10.1186/ar2047

[9]   Masso Gonzalez, E.L., Patrignani, P., Tacconelli, S. and Garcia Rodriguez, L.A. (2010) Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis & Rheumatism, 62, 1592-1601. http://dx.doi.org/10.1002/art.27412

[10]   O’Neil, C.K., Hanlon, J.T. and Marcum, Z.A. (2012) Adverse effects of analgesics commonly used by older adults with osteoarthritis—Focus on non-opioid and opioid analgesics. American Journal of Geriatric Pharmacotherapy, 10, 331-342. http://dx.doi.org/10.1016/j.amjopharm.2012.09.004

[11]   Ruff, K.J., Winkler, A., Jackson, R.W., DeVore, D.P. and Ritz, B.W. (2009) Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: A randomized, multicenter, double-blind, placebo-controlled clinical study. Clinical Rheumatology, 28, 907-914.
http://dx.doi.org/10.1007/s10067-009-1173-4

[12]   Ruff, K.J., DeVore, D.P., Leu, M.D. and Robinson, M.A. (2009) Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. Clinical Interventions in Aging, 4, 235-240. http://dx.doi.org/10.2147/CIA.S5797

[13]   Danesch, U., Seybold, M., Rittinghausen, R., Treibel, W. and Bitterlich, N. (Unpublished) NEM? brand eggshell membrane effective in the treatment of pain associated with knee and hip osteoarthritis: Results from a six-center, open-label german clinical study.

[14]   Wong, M., Hendrix, M.J.C., von der Mark, K., Little and C., Stern, R. (1984) Collagen in the egg shell membranes of the hen. Developmental Biology, 104, 28-36. http://dx.doi.org/10.1016/0012-1606 (84)90033-2

[15]   Baker, J.R. and Balch, D.A. (1962) A study of the organic material of hen’s-egg shell. Biochemical Journal, 82, 352-361.

[16]   Long, F.D., Adams, R.G., DeVore, D.P., Inventors (2005) Preparation of hyaluronic acid from eggshell membrane. US Patent No. 6,946,551.

[17]   Benson, K.F., Ruff, K.J. and Jensen, G.S. (2012) Effects of natural eggshell membrane (nem) on cytokine production in cultures of peripheral blood mononuclear cells: increased suppression of tumor necrosis factor-α levels after in vitro digestion. Journal of Medicinal Food, 15, 360-368.
http://dx.doi.org/10.1089/jmf.2011.0197

[18]   Systat Software, Inc. http://www.systat.com

[19]   Abramson, S.B. and Attur, M. (2009) Developments in the scientific understanding of osteoarthritis. Arthritis Research & Therapy, 11, 227. http://dx.doi.org/10.1186/ar2655

[20]   Sellam, J. and Berenbaum, F. (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nature Reviews Rheumatology, 6, 625-635. http://dx.doi.org/10.1038/nrrheum.2010. 159

[21]   Roach, H.I., Aigner, T., Soder, S., Haag, J. and Welkerling, H. (2007) Pathobiology of osteoarthritis: Pathomechanisms and potential therapeutic targets. Current Drug Targets, 8, 271-282.
http://dx.doi.org/10.2174/138945007779940160

[22]   Sakkas, L.I. and Platsoucas, C.D. (2007) The role of T cells in the pathogenesis of osteoarthritis. Arthritis & Rheumatism, 56, 409-424. http://dx.doi.org/10.1002/art.22369

[23]   Bondeson, J., Wainwright, S.D., Lauder, S., Amos, N. and Hughes, C.E. (2006) The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Research & Therapy, 8, R187. http://dx.doi.org/10.1186/ar2099

[24]   Wenham, C.Y.J. and Conaghan, P.G. (2010) The role of synovitis in osteoarthritis. Therapeutic Advances in Musculoskeletal Diseases, 2, 349-359. http://dx.doi.org/10.1177/1759720X10378373

[25]   Martel-Pelletier, J., Tardif, G., Laufer, S. and Pelletier, J.P. (2005) Cytokines and growth factors in the treatment of osteoarthritis: What could be the best disease modifying drugs. Current Medicinal Chemistry—Anti-Inflammatory & Anti-Allergy Agents, 4, 235-249.

[26]   Yuan, G.H., Masuko-Hongo, K., Kato, T. and Nishioka, K. (2003) Immunologic intervention in the pathogenesis of osteoarthritis. Arthritis & Rheumatism, 48, 602-611. http://dx.doi.org/10.1002/art. 10768

[27]   Yuan, G.H., Masuko-Hongo, K., Sakata, M., et al. (2001) The role of C-C chemokines and their receptors in osteoarthritis. Arthritis & Rheumatism, 44, 1056-1070. http://dx.doi.org/10.1002/1529-0131(200105)44:5%3C1056::AID-ANR186%3E3.0.CO;2-U

[28]   Alaaeddine, N., Olee, T., Hashimoto, S., Creighton-Achermann, L. and Lotz, M. (2001) Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis & Rheumatism, 44, 1633-1643. http://dx.doi.org/10.1002/1529-0131(200107)44:7%3C1633::AID-ART 286%3E3.0.CO;2-Z

[29]   Vergunst, C.E., van de Sande, M.G.H., Lebre, M.C. and Tak, P.P. (2005) The role of chemokines in rheumatoid arthritis and osteoarthritis. Scandinavian Journal of Rheumatology, 34, 415-425.
http://dx.doi.org/10.1080/03009740500439159

[30]   Tanaka, E., Aoyama, J., Miyauchi, M., et al. (2005) Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. Histochemistry and Cell Biology, 123, 275-281. http://dx.doi.org/10.1007/s00418-005-0773-6

[31]   Iannone, F., De Bari, C., Dell’Accio, F., et al. (2001) Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes. Clinical & Experimental Rheumatology, 19, 139-145.

[32]   Ishiguro, N., Ito, T., Ito, H., et al. (1999) Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: Analyses of synovial fluid from patients with osteoarthritis. Arthritis & Rheumatism, 42, 129-136. http://dx.doi.org/10.1002/1529-0131 (199901)42:1%3C129::AID-ANR16%3E3.0.CO;2-4

[33]   US Food and Drug Administration (2005) Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 078932.pdf

 
 
Top